Loading...
•
Sep 30, 2022
ProKidney Q3 2022 Earnings Report
ProKidney listed on the Nasdaq exchange and raised capital to meet clinical milestones.
Key Takeaways
ProKidney reported financial results for the third quarter ended September 30, 2022. The company made significant advancements in its mission to improve the lives and outcomes for people with CKD, including listing on the Nasdaq and raising capital.
Received allowance of the proact 1 Phase 3 study protocol for its investigational candidate REACT by the UK’s MHRA.
Received favorable scientific advice from the EMA on the adequacy of its Phase 3 development program.
Remain on-track and continue to enroll subjects in the proact 1 global Phase 3 randomized, blinded, sham-controlled study.
Successfully completed a listing on Nasdaq raising net proceeds of $512 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...